Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD

Abstract

Indacaterol-glycopyrronium was more effective than salmeterol-fluticasone in preventing COPD exacerbations in patients with a history of exacerbation during the previous year. (Funded by Novartis; FLAME ClinicalTrials.gov number, NCT01782326.).